Cargando…
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
BACKGROUND: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. METHODS: This retr...
Autores principales: | Lamure, Sylvain, Duléry, Rémy, Di Blasi, Roberta, Chauchet, Adrien, Laureana, Cécile, Deau-Fischer, Bénédicte, Drenou, Bernard, Soussain, Carole, Rossi, Cédric, Noël, Nicolas, Choquet, Sylvain, Bologna, Serge, Joly, Bertrand, Kohn, Milena, Malak, Sandra, Fouquet, Guillemette, Daguindau, Etienne, Bernard, Sophie, Thiéblemont, Catherine, Cartron, Guillaume, Lacombe, Karine, Besson, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550257/ https://www.ncbi.nlm.nih.gov/pubmed/33073216 http://dx.doi.org/10.1016/j.eclinm.2020.100549 |
Ejemplares similares
-
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022) -
S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023) -
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019) -
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
por: Tilch, Marie-Kristin, et al.
Publicado: (2022) -
Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy
por: Fouquet, Guillemette, et al.
Publicado: (2021)